$NKTR
NEKTAR THERAPEUTICS

2018 Q2 Form 10-Q Financial Statement

#000156459018020709 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2 2016 Q4
Revenue $1.088B $34.59M $37.45M
YoY Change 3044.69% 5.56% -4.88%
Cost Of Revenue $5.522M $8.989M $6.604M
YoY Change -38.57% 16.62% -21.04%
Gross Profit $1.082B $25.60M $30.85M
YoY Change 4127.32% 2.15% -0.52%
Gross Profit Margin 99.49% 74.01% 82.37%
Selling, General & Admin $20.30M $16.00M $12.80M
YoY Change 26.88% 45.45% -3.03%
% of Gross Profit 1.88% 62.5% 41.5%
Research & Development $88.33M $60.26M $50.23M
YoY Change 46.59% 15.11% 6.57%
% of Gross Profit 8.16% 235.39% 162.85%
Depreciation & Amortization $2.600M $4.300M $3.900M
YoY Change -39.53% 10.26% 2.63%
% of Gross Profit 0.24% 16.8% 12.64%
Operating Expenses $88.33M $60.26M $50.23M
YoY Change 46.59% 15.11% 6.57%
Operating Profit $973.6M -$50.66M -$32.15M
YoY Change -2021.98% 32.17% 9.47%
Interest Expense $5.385M -$9.100M -$9.600M
YoY Change -159.18% -261.72% -10.28%
% of Operating Profit 0.55%
Other Income/Expense, Net $1.745M
YoY Change
Pretax Income $975.3M -$59.80M -$41.80M
YoY Change -1731.01% 23.36% -22.74%
Income Tax $3.885M $100.0K $400.0K
% Of Pretax Income 0.4%
Net Earnings $971.5M -$59.87M -$42.20M
YoY Change -1722.59% 23.18% -22.05%
Net Earnings / Revenue 89.31% -173.09% -112.68%
Basic Earnings Per Share $5.67 -$0.39 -$0.28
Diluted Earnings Per Share $5.33 -$0.39 -$0.28
COMMON SHARES
Basic Shares Outstanding 171.4M shares 155.4M 152.8M
Diluted Shares Outstanding 182.3M shares 155.4M

Balance Sheet

Concept 2018 Q2 2017 Q2 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.824B $265.5M $389.1M
YoY Change 586.93% -3.42% 25.96%
Cash & Equivalents $911.1M $16.15M $59.64M
Short-Term Investments $912.7M $249.4M $329.5M
Other Short-Term Assets $34.90M $7.500M $10.36M
YoY Change 365.33% 38.2% 5.59%
Inventory $11.90M $11.00M $11.11M
Prepaid Expenses
Receivables $35.30M $4.100M $15.68M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.906B $288.2M $426.3M
YoY Change 561.31% -9.46% 21.77%
LONG-TERM ASSETS
Property, Plant & Equipment $45.00M $64.90M $65.60M
YoY Change -30.66% -4.24% -8.04%
Goodwill $76.50M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $282.3M $45.20M
YoY Change 524.56%
Other Assets $3.400M $1.100M $817.0K
YoY Change 209.09% 118.25% 8.36%
Total Long-Term Assets $407.2M $187.7M $142.6M
YoY Change 116.94% 29.65% -4.02%
TOTAL ASSETS
Total Short-Term Assets $1.906B $288.2M $426.3M
Total Long-Term Assets $407.2M $187.7M $142.6M
Total Assets $2.313B $475.9M $568.9M
YoY Change 386.05% 2.76% 14.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.70M $6.200M $2.816M
YoY Change 72.58% 166.32% 19.17%
Accrued Expenses $58.10M $31.90M $35.10M
YoY Change 82.13% -13.78% 55.31%
Deferred Revenue $17.99M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.700M
YoY Change -25.0%
Total Short-Term Liabilities $96.90M $72.60M $72.22M
YoY Change 33.47% -8.43% 17.92%
LONG-TERM LIABILITIES
Long-Term Debt $246.1M $245.4M $243.5M
YoY Change 0.29% 0.04% 0.29%
Other Long-Term Liabilities $7.051M $154.5M $5.000M
YoY Change -95.44% 2466.45% -48.67%
Total Long-Term Liabilities $7.051M $399.9M $5.000M
YoY Change -98.24% 6542.86% -48.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $96.90M $72.60M $72.22M
Total Long-Term Liabilities $7.051M $399.9M $5.000M
Total Liabilities $452.7M $472.5M $480.7M
YoY Change -4.2% -5.94% -2.33%
SHAREHOLDERS EQUITY
Retained Earnings -$1.230B -$2.021B
YoY Change 8.22%
Common Stock $3.094B $2.111B
YoY Change 12.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.860B $3.400M $88.13M
YoY Change
Total Liabilities & Shareholders Equity $2.313B $475.9M $568.9M
YoY Change 386.04% 2.76% 14.08%

Cashflow Statement

Concept 2018 Q2 2017 Q2 2016 Q4
OPERATING ACTIVITIES
Net Income $971.5M -$59.87M -$42.20M
YoY Change -1722.59% 23.18% -22.05%
Depreciation, Depletion And Amortization $2.600M $4.300M $3.900M
YoY Change -39.53% 10.26% 2.63%
Cash From Operating Activities $959.7M -$58.50M -$52.40M
YoY Change -1740.51% 327.01% -30.23%
INVESTING ACTIVITIES
Capital Expenditures -$2.700M -$2.200M -$2.700M
YoY Change 22.73% 46.67% 8.0%
Acquisitions
YoY Change
Other Investing Activities -$891.7M $44.20M -$139.4M
YoY Change -2117.42% -1439.39% 2865.96%
Cash From Investing Activities -$894.4M $42.00M -$142.1M
YoY Change -2229.52% -957.14% 1873.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $189.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 811.0M 9.400M 190.9M
YoY Change 8527.66% 452.94% 60.29%
NET CHANGE
Cash From Operating Activities 959.7M -58.50M -52.40M
Cash From Investing Activities -894.4M 42.00M -142.1M
Cash From Financing Activities 811.0M 9.400M 190.9M
Net Change In Cash 876.3M -7.100M -3.600M
YoY Change -12442.25% -57.99% -109.78%
FREE CASH FLOW
Cash From Operating Activities $959.7M -$58.50M -$52.40M
Capital Expenditures -$2.700M -$2.200M -$2.700M
Free Cash Flow $962.4M -$56.30M -$49.70M
YoY Change -1809.41% 361.48% -31.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
20028000
CY2017Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
9461000
CY2018Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17988000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18949000
CY2018Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
13780000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
19021000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1087717000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34589000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1125735000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59317000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88334000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60260000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
187758000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20261000
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
114117000
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
85245000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
973600000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
9064000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12105000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155352000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166160000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154514000
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182291000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155352000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178281000
CY2018Q2 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
88867000
CY2017Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
94655000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7051000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5992000
CY2018Q2 us-gaap Liabilities
Liabilities
452673000
CY2017Q4 us-gaap Liabilities
Liabilities
421038000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
17000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3094095000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2207865000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4002000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2111000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1229696000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2117941000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
1860414000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
87828000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2313087000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
508866000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
172415000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
159524000
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
172415000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
159524000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123505000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4150000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
232000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-59871000
us-gaap Net Income Loss
NetIncomeLoss
875668000
us-gaap Net Income Loss
NetIncomeLoss
-123737000
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.67
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.27
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.33
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171378000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59684000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
121318000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15996000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38948000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154514000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
873777000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123036000
us-gaap Profit Loss
ProfitLoss
875668000
us-gaap Profit Loss
ProfitLoss
-123737000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
15965000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
13301000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-54000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-54000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
907176000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93089000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2633000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-846205000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28902000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1369000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
790231000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
55208000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
22016000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
845439000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20647000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-47000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
49000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
906363000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-43491000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59640000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16149000
us-gaap Interest Paid Net
InterestPaidNet
9795000
us-gaap Interest Paid Net
InterestPaidNet
10010000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to estimated selling prices of performance obligations and estimates of variable consideration in collaboration agreements, estimated royalty revenue, other estimates required for revenue recognition as described further below, the net realizable value of inventory, the impairment of investments, goodwill and long-lived assets, contingencies, accrued clinical trial, contract manufacturing and other expenses, estimated non-cash royalty revenue and non-cash interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified.</p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating income (loss), net income (loss), total assets, liabilities or stockholders&#8217; equity. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Concentrations</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe <font style="color:#000000;">and with whom we have multi-year arrangements</font>. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; payment histories and associated credit risk. We have not experienced significant credit losses from our accounts receivable and our allowance for doubtful accounts was not significant at either June 30, 2018 or December&#160;31, 2017.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</p></div>
CY2018Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
2106085000
CY2018Q2 us-gaap Senior Notes
SeniorNotes
250000000
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2020-10-05
nktr Number Of Operating Business Segment
NumberOfOperatingBusinessSegment
1
CY2018Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
1900000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
353220000
nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
Two years or less
nktr Debt Investment Maturity Date Description
DebtInvestmentMaturityDateDescription
One year or less
CY2018Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2017Q2 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2018Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1996321000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
347326000
CY2018Q2 nktr Cash And Restricted Cash
CashAndRestrictedCash
2752000
CY2017Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
4460000
CY2018Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1807000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1796000
CY2018Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9483000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4843000
CY2018Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
594000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4087000
nktr Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
0.17
nktr Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
0.176
nktr Prospective Interest Rate Percentage
ProspectiveInterestRatePercentage
0.21
CY2018Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
1064246000
CY2017Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
4824000
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
1077973000
nktr Revenue Recognized In Period Related To Performance In Prior Periods
RevenueRecognizedInPeriodRelatedToPerformanceInPriorPeriods
45600000
CY2018Q2 nktr Revenue Recognized In Period Related To Performance In Prior Periods
RevenueRecognizedInPeriodRelatedToPerformanceInPriorPeriods
17600000
CY2017Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37970000
nktr Increase In Contract With Customer Liability For Consideration
IncreaseInContractWithCustomerLiabilityForConsideration
4000000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
8249000
CY2018Q2 nktr Potential Development And Regulatory Milestones
PotentialDevelopmentAndRegulatoryMilestones
1700000000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20660000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8099000
CY2018Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1750908
CY2017Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1130164
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
4605724
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
2648769
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10900000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
12100000

Files In Submission

Name View Source Status
0001564590-18-020709-index-headers.html Edgar Link pending
0001564590-18-020709-index.html Edgar Link pending
0001564590-18-020709.txt Edgar Link pending
0001564590-18-020709-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g3z1renem02l000001.jpg Edgar Link pending
g3z1renem02l000002.jpg Edgar Link pending
g3z1renem02l000003.jpg Edgar Link pending
g3z1renem02l000004.jpg Edgar Link pending
g3z1renem02l000005.jpg Edgar Link pending
g3z1renem02l000006.jpg Edgar Link pending
nktr-10q_20180630.htm Edgar Link pending
nktr-20180630.xml Edgar Link completed
nktr-20180630.xsd Edgar Link pending
nktr-20180630_cal.xml Edgar Link unprocessable
nktr-20180630_def.xml Edgar Link unprocessable
nktr-20180630_lab.xml Edgar Link unprocessable
nktr-20180630_pre.xml Edgar Link unprocessable
nktr-ex101_86.htm Edgar Link pending
nktr-ex311_8.htm Edgar Link pending
nktr-ex312_6.htm Edgar Link pending
nktr-ex321_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending